<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04109534</url>
  </required_header>
  <id_info>
    <org_study_id>19-263</org_study_id>
    <nct_id>NCT04109534</nct_id>
  </id_info>
  <brief_title>Effect of a Dietary Fatty Acid Supplementation on Symptoms and Bronchial Inflammation in Patients With Asthma</brief_title>
  <acronym>LCPUFA</acronym>
  <official_title>Investigation of the Effect of a Dietary Fatty Acid Supplementation on Symptoms and Bronchial Inflammation in Patients With Asthma and House Dust Mite Allergy After Repeated Allergen Challenge</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stefan Zielen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study will investigate the effect of a polyunsaturated fatty acid / lipid
      mixture (LCPUFAs) on the clinical symptoms, bronchial inflammation and lung function in
      allergic asthma in a bronchial allergen provocation (BAP) model. For this purpose, patients
      with stable episodic asthma and dust mite allergy will underwent BAP before and after
      supplementation with LCPUFAs. The clinical symptoms, bronchial inflammation, exhaled NO
      increase and lung function decline (FEV1) will be analyzed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Asthma is a chronic lung disease, which is characterized by recurrent obstruction, a
      hypersensitivity and a chronic inflammation of the airway. It is known that LCPUVAs could
      reduce the production of inflammatory mediators. In addition, LCPUVAs can improve pulmonary
      function, with a concurrent reduction in bronchodilator use in patients with asthma. Subjects
      suffering from episodic asthma and house dust mite (HDM) allergy usually have a normal lung
      function testing at rest and show a decrease in lung function when they are exposed to HDM.
      Bronchial allergen provocation models are well established in asthma research and allow the
      evaluation of anti-allergic and anti-asthmatic agents in relatively small sample sizes. In a
      previous study the investigators could show, that LCPUVAs could reduce exhaled NO after
      repeated BAP with HDM.

      In this study the investigators will investigate the protective effect of LCPUVAs in a
      repeated BAP model. Clinical symptoms (nasal and bronchial), exhaled NO, decrease in lung
      function the early asthmatic reaction (EAR), the late asthmatic reaction (LAR) and blood
      parameters (Triglyceride and Cholesterin and mircro RNAs) will be measured before and after
      LCPUVA supplementation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Placebo-controlled prospective study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>LCPUVAS and Placebo are provided in sealed bags</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Decrase of exhaled NO (eNO) after BAP</measure>
    <time_frame>4 weeks</time_frame>
    <description>After BAP with HDM the decrease of eNO will be compared between placebo and active comparator. A relevant decrease is defined as a drop of 30% of exhaled NO.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute levels eNO</measure>
    <time_frame>4 weeks</time_frame>
    <description>Comparison of absolute levels eNO (ppb)at end of treatment between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnitude of EAR</measure>
    <time_frame>4 weeks</time_frame>
    <description>Comparison of EAR (maximum decrease of FEV1) at end of treatment between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnitude of LAR</measure>
    <time_frame>4 weeks</time_frame>
    <description>Comparison of LAR (maximum decrease of FEV1 in %) at end of treatment between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 after BAP</measure>
    <time_frame>4 weeks</time_frame>
    <description>Comparison of FEV1 Levels 24 hours after BAP between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of methacholin levels</measure>
    <time_frame>4 weeks</time_frame>
    <description>Comparison of methacholin (mg) Levels 24 hours after BAP between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma control test (ACT)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Comparison of ACT score between Groups at end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Salbutamol use</measure>
    <time_frame>4 days</time_frame>
    <description>Cumulative Salbutamol use in the last 4 days of treatment during repetitive BAP between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lebel symptom score</measure>
    <time_frame>4 weeks</time_frame>
    <description>Comparison of Lebel symptom score after nasal provocation test (NPT), before and after supplementation between groups. A lebel score of 0-4 is negative, a lebel score &gt;5 positive, the maximum result is 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak nasal expiratory flow</measure>
    <time_frame>4 weeks</time_frame>
    <description>Comparison of peak nasal expiratory flow (PNIF) after NPT between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analog scala (VAS)-score after NPT</measure>
    <time_frame>4 weeks</time_frame>
    <description>Comparison of VAS (mm) after NPT between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analog scala (VAS)-score for nasal symptoms</measure>
    <time_frame>5 days</time_frame>
    <description>Comparison of cumulative VAS-score for 4 nasal symptoms (Total mm each symptom) in the last 5 days of treatment during repetitive BAP between groups</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Levels of LCPUFA</measure>
    <time_frame>4 weeks</time_frame>
    <description>Levels of LCPUFA will be measured before and after Supplementation between groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Levels of triglyceride and cholesterin</measure>
    <time_frame>4 weeks</time_frame>
    <description>Levels of triglyceride and cholesterin will be measured before and after supplementation between groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Levels of eosinophils</measure>
    <time_frame>4 weeks</time_frame>
    <description>Levels of eosinophils will be measured after supplementation and 24 hours after BAP between groups</description>
  </other_outcome>
  <other_outcome>
    <measure>micro RNAs</measure>
    <time_frame>4 weeks</time_frame>
    <description>Levels of micro RNAs will be measured before supplementation and before and 24 hours after BAP between groups</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Allergic Asthma</condition>
  <condition>Allergy to House Dust Mite</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator 20 patients aged 18-45 years with a diagnosis of HDM induced allergic asthma and an increase of exhaled NO of 30% after BAP will be randomized to the Placebo Comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Verum</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PUFAS: 2640 mg of middle-chain and polyunsaturated fatty acids 20 patients aged 18-45 years with a diagnosis of HDM induced allergic asthma and an increase of exhaled NO of 30% after BAP will be randomized to the Active Comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Bronchial allergen provocation (BAP)</intervention_name>
    <description>Nebulized Dermatophagoides farina administered at following doses: 10AE, 20 AE, 40 AE, 80 160 AE, etcâ€¦ until the FEV1 decreases 20% below the initial FEV1-value</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Verum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Nasal provocation test (NPT)</intervention_name>
    <description>Dermatophagoides farina will be administered in both nostrils</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Verum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Methacholine test</intervention_name>
    <description>Nebulized metacholine will be administered at following doses: 0,01mg, 0,1mg, 0,4mg, 0,8mg und 1,6mg until the FEV1 decreases 20% below the initial FEV1-value</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Verum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Peak nasal expiratory flow (PNIF)</intervention_name>
    <description>Comparison of peak nasal expiratory flow (PNIF) after NPT between groups</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Verum</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

               -  Patients: aged â‰¥18 and 45 years

               -  known allergen induced asthma and HDM-Allergy

               -  basic lung function FVC â‰¥ 80%, FEV1 â‰¥ 75%

               -  decrease in FEV1 after BAP â‰¥ 20%

               -  30% increase of NO after BAP

        Exclusion Criteria:

          -  lung function Forced vital capacity (FVC) &lt;80% and Forced expiratory volume in 1
             second (FEV1) &lt;75%

          -  chronic diseases or infections (e.g. HIV, Tbc)

          -  pregnancy

          -  systemic corticosteroid-treatment

          -  inhalative corticosteroid therapy or leukotriene antagonists

          -  alcohol, substance or drug abuse

          -  current smokers

          -  inability to capture extend and consequences of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Zielen, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik fÃ¼r Kinder- und Jugendmedizin UniversitÃ¤tsklinikum</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefan Zielen, Professor</last_name>
    <phone>+496301</phone>
    <phone_ext>83349</phone_ext>
    <email>Stefan.Zielen@kgu.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susanne Middelkamp</last_name>
    <phone>+496301</phone>
    <phone_ext>83349</phone_ext>
    <email>Susanne.Middelkamp@kgu.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinik fÃ¼r Kinder- und Jugendmedizin UniversitÃ¤tsklinikum</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Zielen, Professor</last_name>
      <phone>+49 696301</phone>
      <phone_ext>83063</phone_ext>
      <email>Stefan.zielen@kgu.de</email>
    </contact>
    <contact_backup>
      <last_name>Paola JE Gnago, MD</last_name>
      <phone>+4915780560152</phone>
      <email>Paola.Gnago@kgu.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 27, 2019</study_first_submitted>
  <study_first_submitted_qc>September 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2019</study_first_posted>
  <last_update_submitted>September 29, 2019</last_update_submitted>
  <last_update_submitted_qc>September 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospital</investigator_affiliation>
    <investigator_full_name>Stefan Zielen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>allergic asthma,</keyword>
  <keyword>house dust mite allergy</keyword>
  <keyword>bronchial allergen provocation</keyword>
  <keyword>LCPUFAs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methacholine Chloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized data will be provided of the investigated cohort</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>After end of study anticipated June 2020</ipd_time_frame>
    <ipd_access_criteria>The data will be available after the end of study and successful publication of the results (anticipated June 2021 for 10 years</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

